Compare Illumina, Inc. (ILMN) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs State Street SPDR S&P Biotech ETF — how do they compare? Illumina, Inc. trades at $192.8 (market cap $27.94B), while State Street SPDR S&P Biotech ETF trades at $154.49. The key difference: Illumina, Inc. is trading nearer its 52-week high, State Street SPDR S&P Biotech ETF nearer its low. Which is the better fit depends on your goals.
| ILMN | XBI | |
|---|---|---|
Market Cap | $27.94B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $194.33 | $164.28 |
52-Week Low | $91.00 | $85.16 |
Enterprise Value | $29.33B | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
